Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

532
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
532
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

694
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
694
Drug Therapy01:28

Drug Therapy

140
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
140
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

306
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
306
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.0K
Dementia01:30

Dementia

276
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
276

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Brexpiprazole side-effect profile in people with agitation in Alzheimer's dementia: a plain language summary.

Current medical research and opinion·2026
Same author

Current and Emerging Pharmacological Approaches to Agitation in Alzheimer's Disease: A Narrative Review of New and Repurposed Therapies.

Drugs·2025
Same author

Brexpiprazole for agitation in clinically relevant patient subgroups: a <i>post hoc</i> analysis of efficacy and safety in patients with agitation associated with dementia due to Alzheimer's disease.

Current medical research and opinion·2025
Same author

Ageism and Its Correlates Among Lebanese Healthcare Workers.

Sage open aging·2025
Same author

Use of Psychedelic Agents in Older Adults with Treatment-Resistant Major Depressive Disorder: What the Evidence Shows.

Drugs & aging·2025
Same author

A US-based practitioner's guide to diagnosis, evaluation, and evidence-based treatment of agitation in Alzheimer's dementia - recommendations of an expert, multispecialty advisory panel.

Postgraduate medicine·2025

Related Experiment Video

Updated: Nov 9, 2025

Fluorescence-Activated Cell Sorting-Radioligand Treated Tissue FACS-RTT to Determine the Cellular Origin of Radioactive Signal
12:04

Fluorescence-Activated Cell Sorting-Radioligand Treated Tissue FACS-RTT to Determine the Cellular Origin of Radioactive Signal

Published on: September 10, 2021

2.6K

Pharmacotherapy for Frontotemporal Dementia.

Rita Khoury1,2,3, Yu Liu4, Quratulanne Sheheryar4

  • 1Department of Psychiatry and Clinical Psychology, Saint Georges Hospital University Medical Center, Youssef Sursock Street, PO Box 166378, Beirut, Lebanon. rita.khoury@idraac.org.

CNS Drugs
|April 11, 2021
PubMed
Summary
This summary is machine-generated.

Frontotemporal dementia (FTD) is a group of brain disorders with no approved treatments. Research is advancing to develop new therapies targeting genetic causes and protein deposits like tau.

More Related Videos

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.7K
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

502

Related Experiment Videos

Last Updated: Nov 9, 2025

Fluorescence-Activated Cell Sorting-Radioligand Treated Tissue FACS-RTT to Determine the Cellular Origin of Radioactive Signal
12:04

Fluorescence-Activated Cell Sorting-Radioligand Treated Tissue FACS-RTT to Determine the Cellular Origin of Radioactive Signal

Published on: September 10, 2021

2.6K
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
09:22

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

18.7K
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

502

Area of Science:

  • Neuroscience
  • Genetics
  • Neuropathology

Background:

  • Frontotemporal dementia (FTD) is a diverse group of neurodegenerative disorders.
  • Pathologically, FTD is characterized by tau, TAR DNA-binding protein 43 (TDP-43), or fused in sarcoma (FUS) inclusions.
  • Genetic mutations and phenotypic variations, including behavioral variant FTD and primary progressive aphasia, contribute to its complexity.

Purpose of the Study:

  • To review the current understanding of frontotemporal dementia (FTD) pathophysiology.
  • To summarize the limitations of existing therapies for FTD.
  • To highlight emerging therapeutic strategies for FTD.

Main Methods:

  • Literature review of neuropathological, genetic, and clinical findings in FTD.
  • Analysis of current treatment approaches and their evidence base.
  • Examination of novel therapeutic targets and clinical trial considerations.

Main Results:

  • No approved symptomatic or disease-modifying treatments currently exist for FTD.
  • Existing therapies have limited efficacy and carry risks, including confusion and mortality.
  • Emerging treatments focus on progranulin, C9orf72 gene expansions, and tau pathology.

Conclusions:

  • Significant unmet needs exist for effective FTD treatments.
  • Further research into disease mechanisms and improved clinical trial design are crucial.
  • Targeting specific genetic and protein pathways holds promise for future FTD therapies.